Abstract 724 Table 1 Median time to next treatment by number of risk factors (95% CI), months

Type of treatment	High-risk category (≥1 risk factor)	Number of risk factors				
		0	1	2	3	4
MT	13.3 (11.1–16.3)	28.8 (10.8–NA)	19.3 (13.5–30.6)	17.8 (12.8–22.5)	10.6 (7.0–13.4)	6.7 (6.2–8.4)
AS	9.0 (8.0–9.9)	26.4 (14.7–47.8)	17.7 (13.4–23.3)	11.3 (9.2–12.5)	6.5 (5.8–7.7)	4.0 (3.5–4.4)

AS, active surveillance; CI, confidence interval; MT, maintenance therapy; NA, not achieved.

28, 2021, from the Flatiron Health electronic health record-derived de-identified US database. Patients ≥18 years old, with stage III/IV disease, who received 1L platinum-based therapy, had ECOG performance score of 0/1, and had ≥12 weeks of follow-up after 1L treatment were included. Patients were classified into 2 risk categories: moderate risk (stage III disease, no visible residual disease, primary debulking surgery, and *BRCA* mutant) or high risk (presence of ≥1 of the following: stage IV disease, visible residual disease, interval debulking surgery/no surgery, or *BRCA* wild type/unknown status). High-risk patients were further grouped by total number of RFs. Patients were followed from index date (ID), defined as end of 1L treatment. The target trial emulation method was used to account for potential selection and immortal time biases. Patients were classified as having received MT if MT was started within 120 days of ID.

Result(s)* Of the 1251 patients with advanced OC evaluated, 26% (n=323) initiated 1L MT and 74% (n=928) did not. Of patients who received MT, 5% (n=16) were moderate risk and 95% (n=307) were high risk. Only 4% (n=34) of AS patients were moderate risk and 96% (n=894) were high risk. Time to next treatment (TTNT) decreased with more RFs (table 1). Notably, among patients in the high-risk category, median TTNT was longer in patients who received 1L MT than in those who received AS (table 1).

Conclusion* The number of RFs impacted the risk of PD, irrespective of the type of treatment the patient received after completion of 1L treatment. For high-risk patients, greater TTNT prolongation was associated with 1L MT but not AS.

727

HRD SCORING WITH A SNP ASSAY

T McKea*, Y Christinat, S Leboube, L Ho. *Hôpitaux Universitaires de Genève (HUG), Genève, Switzerland*

10.1136/ijgc-2021-ESGO.456

Introduction/Background* Homologous recombination deficiency (HRD) is a well-known characteristic of *BRCA*-mutated tumors, an alteration present in ~30% of ovarian cancers and with different frequencies in breast, prostate and pancreatic cancers. The PAOLA-1 trial demonstrated that responders to Poly (ADP-ribose) polymerase (PARP) inhibitors do not only include *BRCA*-mutated tumors but also tumors that are *BRCA*-wildtype and display an HRD phenotype. Given its importance, many different scores and technologies have been proposed and commercialized to assess the HRD phenotype. Nonetheless many of these solutions are expensive and/or complicated to implement in practice.

Methodology We propose a novel HRD scoring algorithm based copy number alterations obtained from a clinical-grade

SNP assay that works on FFPE samples (ThermoFisher Onco-scan Assay). The method has been evaluated on 400 high-grade ovarian carcinoma and 100 triple-negative breast cancer samples from the TCGA cohort. A validation was performed on an internal cohort of 50 ovarian cancers.

Result(s)* The algorithm performed better than two well-known commercial methods, the compound score from Telli et al. (LST+LOH+TAI) and the percentage of LOH bases across the genome, and classified correctly the *BRCA*-mutated cancers into the HRD category.

Conclusion* The high concordance with the LST+LOH+TAI score led to its inclusion into the clinical routine at the Geneva University Hospitals. The method is also being evaluated as a biomarker to predict response to Olaparib as part of phase 3 of the ENGOT HRD European Initiative (EHEI).

729

THE IMPACT OF AGE AND PERFORMANCE STATUS ON THE MANAGEMENT OF PATIENTS WITH OVARIAN CANCER: A MULTICENTRIC STUDY

¹ME Laudani*, ²L Fuso, ¹M Barboni, ¹G Parpinel, ¹E Peirano, ²M Villa, ³F Moro, ²A Ferrero, ¹P Zola. ¹University of Turin, Surgical Sciences, Torino, Italy; ²AO Ordine Mauriziano, Gynecology and Obstetrics, Turin, Italy; ³Città della Salute e della Scienza di Torino, Turin, Italy

10.1136/ijgc-2021-ESGO.457

Introduction/Background* Incidence of ovarian cancer increases with age and reaches a peak at 70 years. The aim of the present study is the analysis of therapeutic differences, both surgical and pharmacological, in patients affected by ovarian cancer and stratified by age.

Methodology A multicentre retrospective study has been conducted. Patients with ovarian cancer were included and ranked at diagnosis in group A (≥70 years) and group B (<70 years). Co-morbidities, performance status, FIGO stage, grading, histotype and treatment were considered. Surgical treatment was considered as primary debulking surgery or interval debulking surgery (IDS) reporting extension, residual tumour, complications and days of hospitalization. Chemotherapy was administered for 3 or more cycles and the clinical response was evaluated.

Result(s)* 459 patients were included in the study, 132 (28.8%) in group A and 327 (71.2%) in group B. Considering advanced stages optimal cytoreduction was achieved in 76.7% of younger patients and in 66.7% of older (p=0.05). IDS was especially necessary in the elderly compared to the young ones (37.9% vs 49%; p=0.05). There was good correlation between overall survival and the performance status (p=0.0001), the age at diagnosis (p=0.001), tumour stage (p=0.0001) and residual tumour (p=0.00001).